Quick dissolving oral dosage forms: Scientific and regulatory considerations from a clinical pharmacology and biopharmaceutics perspective

Drug Delivery to the Oral Cavity: Molecules to Market

Volumn , Issue , 2005, Pages 337-356

  Ghosh, Tapash K ^a   Chatterjee, Dhruba J ^a   Pfister, William R ^b   Jarugula, Venkateswar R ^a   Fadiran, Emmanuel O ^a   Hunt, John P ^a   Lesko, Lawrence J ^a   Tammara, Vijaya K ^c   Hare, Donald B ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NexMed Inc   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85012879869     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (36)

1. Electronic Orange Book, 2003, www.fda.gov/cder/ob/default.htm.
2. Claritin Reditabs 24 hour Non-drowsy Orally Disintegrating Tablets (Schering-Plough) Brand of Loratadine (PPI). PDR.Net, Thomson Healthcare, Montvale, NJ, 2003, http://www.pdr.net/HomePage_template.jsp.
3. European Directorate for the Quality of Medicines, Pharmeuropa 10 (4):547, 1988, http://www.pheur.org.
4. CDER Data Standards Manual, 2003, www.fda.gov/cder/dsm/DRG/drg00201.htm.
5. M.E. de Vries et al., Developments in buccal drug delivery, Crit. Rev. Ther. Drug Carr. Sys., 8:271, 1991.
6. M.J. Rathbone and J. Hadgraft, Absorption of drugs from the human oral cavity, Int. J. Pharm., 74:9, 1991.
7. C.A. Squier, The permeability of oral mucosa, Crit. Rev. Oral Biol. Med. 2:13, 1991.
8. H.P. Merkle and G.J.M. Wolnay, Muco-adhesive patches for buccal peptide administration, Minutes, European Symposium, Buccal and nasal administration as an alternative to parenteral administration (D. Duchne, ed.), Editions de Santé, Paris, p. 110, 1992.
9. D. Harris and J.R. Robinson, Drug delivery via the mucous membranes of the oral cavity, J. Pharm. Sci., 81:1, 1992.
10. M.J. Rathbone et al., The oral cavity as a site for systemic drug delivery, Adv. Drug Del. Rev., 13:1, 1994.
11. Federal Register, Supt. of Documents, U.S. Government Printing Office, Washington, DC, 2002, http://www.access.gpo.gov/su_docs/index.htm.
12. Code of Federal Regulations, Title 21, Supt. of Documents, U.S. Government Printing Office, Washington, DC, 2002, http://www.access.gpo.gov/su_docs/index.htm.
13. Code of Federal Regulations, U.S. Government Printing Office, Washington, DC, http://www.gpoaccess.gov/cfr/index.html, Title, 21, Volume 4, Revised April 1, 2003, Chapter I-Food and Drug Administration, Department of Health and Human Services, Part 201-Labeling.
14. Code of Federal Regulations, U.S. Government Printing Office, Washington, DC, http://www.gpoaccess.gov/cfr/index.html, Title, 21, Volume 5, Revised April 1, 2003, Chapter I-Food and Drug Administration, Department of Health and Human Services, Part 320-Bioavailability and Bioequivalence Requirements.
15. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance Documents, http://www.fda.gov/cder/guidance.
16. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), http://www.ich.org.
17. C.C. Faura et al., Systemic review of factors affecting the ratios of morphine and its major metabolites, Pain, 74:43, 1998.
18. S.V. Sastry, K. Ostrander, J.S. Chu, V. Agarwal, and T.K. Ghosh, Annual AAPS Symposium: Oral Fast Dispersing Delivery Systems-Recent Advances, Salt Lake City, Utah, October 29, 2003.
19. W. Sawicki and S. Janicki, Pharmacokinetics of verapamil and its metabolites norverapamil from a buccal drug formulation, Int. J. Pharm., 238:181, 2002.
20. B.J. Lipworth et al., Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma, Eur. J. Clin. Pharmacol., 37 (6):567, 1989.
21. D. Harris and J.R. Robinson, Drug delivery via the mucous membranes of the oral cavity, J. Pharm. Sci., 81(1):1, 1992.
22. D. Brown, Orally disintegrating tablets-Taste over speed, Drug Delivery Technology, 3(6):58.
23. K. Cremer, Orally disintegrating dosage forms. Industry Summary Report. Pharma Concepts GMbH and Co., 2001: www.pharma-concepts.com.
24. W. Habib et al., Fast-dissolve drug delivery systems, Crit. Rev. Ther. Drug Carrier Sys., 17(1):61, 2000.
25. Zofran® ODT Patient Package Insert (PPI), PDR.Net, Thomson Healthcare, Montvale, NJ, 2003: http://www.pdr.net/HomePage_template.jsp.
26. Maxalt-MLT® Patient Package Insert (PPI), PDR.Net, Thomson Healthcare, Montvale, NJ, 2000: http://www.pdr.net/HomePage_template.jsp.
27. Zomig-ZMT® Patient Package Insert (PPI), PDR.Net, Thomson Healthcare, Montvale, NJ, 2002: http://www.pdr.net/HomePage_template.jsp.
28. Amarin press release, Amarin Corporation Announces Acceptance for Filing of New Drug Application for Zelapar by U.S. FDA, May 23, 2002.
29. Guidance for Industry, Food-Effect Bioavailability and Fed Bioequivalence Studies, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), January, 2003, http://www.fda.gov/cder/guidance/5194fnl.htm.
30. International Conference on Harmonization; Guidance on Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, Federal Register, 65(251):83041-83063, December 29, 2000, http://www.fda.gov/OHRMS/DOCKETS/98fr/122900d.pdf.
31. P. Chue et al., Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine patients with schizophrenia, CJP, 47:771, 2002.
32. M. Siewert et al., FIP/AAPS Guidelines for dissolution/in vitro release testing of novel/special dosage forms, Dissolution Technologie, Feb 6, 2003.
33. USP-NF Online, USP26-NF21S2, United States Pharmacopeial Convention, Inc., http://www.uspnf.com/uspnf/usp26-nf21s2/default.htm.
34. Guidance for Industry, Waiver of in vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), August 2000, http://www.fda.gov/cder/guidance/3618fnl. pdf.
35. Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), March 2003, http://www.fda.gov/cder/guidance/5356fnl.htm.
36. R.-K. Chang et al., Fast-dissolving tablets, Pharm. Tech., June: 52, 2000.